市場調查報告書

何杰金氏淋巴瘤的治療方法的全球市場:成長率、趨勢、預測

Hodgkin Lymphoma Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 546541
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
Back to Top
何杰金氏淋巴瘤的治療方法的全球市場:成長率、趨勢、預測 Hodgkin Lymphoma Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

本報告提供何杰金氏淋巴瘤的各種治療方法、治療藥的市場相關分析,疾病概要和現在/未來可利用的治療選擇,主要的促進、阻礙因素,市場規模趨勢預測 (今後6年份),各領域、各地區的詳細趨勢,近幾年的市場競爭的動向,主要企業簡介等調查。

第1章 簡介

第2章 分析方法

第3章 摘要整理

第4章 主要考察事項

第5章 市場概要、產業趨勢

  • 目前市場方案
  • 市場概要
  • 波特的五力分析

第6章 推動、市場的阻礙要素/機會/課題分析 (DROC分析)

  • 市場的推動要素
  • 市場的阻礙要素
  • 市場機會
  • 主要課題

第7章 全球輸卵管癌症市場:各領域

  • 治療方法的種類
    • 手術
    • 化療
    • 放射治療

第8章 全球輸卵管癌症市場:各地區的市場規模、佔有率預測

  • 北美 (美國,加拿大,墨西哥)
  • 歐洲 (德國,英國,法國,義大利,西班牙、葡萄牙,北歐各國,荷比盧三國等)
  • 亞太地區 (中國,日本,印度,澳洲、紐西蘭,韓國等)
  • 中東、非洲 (波灣合作理事會 (GCC) 各國,南非等)
  • 南美 (巴西,阿根廷等)

第9章 競爭環境

  • 企業合併、收購 (M&A) 分析
  • 新產品的銷售
  • 協定,產業合作、聯盟

第10章 企業簡介

  • Amgen Inc.
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Celgene
  • Eli Lilly and Company
  • Roche
  • 其他

第11章 投資機會相關分析師的見解

第12章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 55414

Hodgkin's lymphoma is a malignant tumor that develops from cells in the lymphatic system called lymphocytes. The cancer is characterized histologically by the presence of multinucleated giant cells called Reed-Sternberg cells and associated abnormal, smaller mononuclear cells originating from B-lymphocytes in the germinal centers of lymphoid tissue. Global statistics show that the number of new cases of Hodgkin's lymphoma is 2.6 per 100,000 men and women, per year. Unlike most cancers, the chances of Hodgkin's lymphoma do not increase with age; they are found to be high in two age groups, young adults and the elderly. The increase in the number of new cases diagnosed every year is expected to drive the Hodgkin's lymphoma treatment market.

Key Market Trends

Radiotherapy Segment is Expected to Register a Significant Growth over the Forecast Period

Based on Treatment Type, it is segmented into Chemotherapy, Radiotherapy, and Others. Radiotherapy is a well-established technique at destroying Hodgkin's disease cells by using high-energy beams or particles to kill cancer cells and may be delivered from a source outside the body, i.e., external beam radiation or internally, such as brachytherapy. For classical Hodgkin's disease, radiotherapy is often given after chemotherapy, especially when there is a large or bulky tumor mass. According to the American Cancer Society, in 2019, around 8,110 people in the United States were diagnosed with Hodgkin lymphoma. Hence, the rising burden of cancer, along with increasing awareness about hodgkin's lymphoma, the market is expected to grow in the forecast period.

North America Expected to Hold the Largest Share in the Hodgkin Lymphoma Treatment Market

The hodgkin lymphoma treatment market expected to hold the largest share in the North America region. According to the American Cancer Society estimates, in 2019, there were around 1,000 deaths (410 women and 590 men) from Hodgkin's lymphoma in the United States. Hodgkin lymphoma affects both children and adults. It is the most commonly diagnosed cancer in teens aged 15 to 19 years. The increasing number of new cases, developed healthcare infrastructure and advanced treatment options are contributing to the growth of the studied market.

Competitive Landscape

The global players into the hodgkin lymphoma treatment market are Alkem Laboratories, Amneal Pharmaceuticals, Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, F Hoffmann-La Roche Ltd, Incyte Corp, Merck & Co. Inc., Seattle Genetics, Inc. and Teva Pharmaceutical Industries Ltd.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Hodgkin Lymphoma
    • 4.2.2 Increasing Awareness about Hodgkin Lymphoma
    • 4.2.3 High Unmet Need in Older Patients and Patients with Relapsed or Refractory (R/R) HL
  • 4.3 Market Restraints
    • 4.3.1 Adverse Long-term Side Effects
    • 4.3.2 High Cost of Treatment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment Type
    • 5.1.1 Chemotherapy
    • 5.1.2 Radiotherapy
    • 5.1.3 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Alkem Laboratories
    • 6.1.2 Amneal Pharmaceuticals, Inc.
    • 6.1.3 Baxter International Inc.
    • 6.1.4 Biogen Inc.
    • 6.1.5 Bristol-Myers Squibb Company
    • 6.1.6 F Hoffmann-La Roche Ltd
    • 6.1.7 Incyte Corp
    • 6.1.8 Merck & Co. Inc.
    • 6.1.9 Seattle Genetics, Inc.
    • 6.1.10 Teva Pharmaceutical Industries Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top